Clinical trial
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive…
NCT00006358 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00006358 |
|---|---|
| Title | Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor |
| Official title | Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | temozolomide, thalidomide |
| Enrollment | 44 |
| Start date | Jun 13, 2000 |
| Primary completion | Jan 23, 2003 |
| Completion | Jul 20, 2006 |
| First posted | May 26, 2004 |
| Last update posted | Jun 26, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: